FDA Grants Full Approval for Blincyto (blinatumomab) to Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
Conversion From Accelerated to Full Approval
Reinforces Blincyto as Standard of Care for Patients With Minimal Residual Disease at Baseline After Remission
THOUSAND OAKS, Calif., June 21, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news